{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:56:55Z","timestamp":1794898615676,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jhep.2022.11.028","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T19:54:28Z","timestamp":1670961268000},"page":"852-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["NAFLD and NASH biomarker qualification in the LITMUS consortium \u2013 Lessons learned"],"prefix":"10.1016","volume":"78","author":[{"given":"Daniel Guldager Kring","family":"Rasmussen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Torstenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Brass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8285-2204","authenticated-orcid":false,"given":"Stephen","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Billin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7881-4205","authenticated-orcid":false,"given":"Anneli","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-2063","authenticated-orcid":false,"given":"Elizabeth","family":"Shumbayawonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Schoelch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Yunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-0128","authenticated-orcid":false,"given":"Patrick","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.11.028_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.healthpol.2010.12.002","article-title":"The cost of drug development: a systematic review","volume":"100","author":"Morgan","year":"2011","journal-title":"Health Policy"},{"key":"10.1016\/j.jhep.2022.11.028_bib2","series-title":"Examination of clinical trial costs and barriers for drug development","author":"Sertkaya","year":"2014"},{"key":"10.1016\/j.jhep.2022.11.028_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.760762","article-title":"R&D costs of new medicines: a landscape analysis","volume":"8","author":"Simoens","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.jhep.2022.11.028_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib5","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the\u00a0management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.11.028_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.11.028_bib9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cgh.2011.03.020","article-title":"Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008","volume":"9","author":"Younossi","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.11.028_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib13","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.11.028_bib14","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.11.028_bib15","article-title":"Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study","author":"Fujii","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib16","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.11.028_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2021.11.005","article-title":"Liquid biomarkers for fibrotic NASH - progress in a complex field","volume":"76","author":"Schuppan","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib19","unstructured":"LITMUS: Liver Investigation: Testing Marker Utility in Steatohepatitis consortium (European Union IMI2-funded under Grant Agreement 777377). https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/litmus."},{"key":"10.1016\/j.jhep.2022.11.028_bib20","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpt.264","article-title":"Industry perspectives on biomarker qualification","volume":"99","author":"Lavezzari","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.11.028_bib21","series-title":"BEST (biomarkers, EndpointS, and other tools) resource","first-page":"1","year":"2018"},{"key":"10.1016\/j.jhep.2022.11.028_bib22","series-title":"Final recommendation statement abnormal blood glucose and type 2 diabetes mellitus: screening","year":"2015"},{"key":"10.1016\/j.jhep.2022.11.028_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.11.028_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: the anti-BLyS-lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jhep.2022.11.028_bib25","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: national Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jhep.2022.11.028_bib26","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic\u00a0fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhep.2022.11.028_bib27","doi-asserted-by":"crossref","first-page":"694","DOI":"10.12968\/hmed.2018.79.12.694","article-title":"The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis","volume":"79","author":"Day","year":"2018","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.jhep.2022.11.028_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","article-title":"Factor v Leiden thrombophilia","volume":"13","author":"J.L.","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.jhep.2022.11.028_bib29","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.11.028_bib30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.11.028_bib31","article-title":"Standards of medical care in diabetes","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2022.11.028_bib32","series-title":"Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment guidance for industry DRAFT GUIDANCE","year":"2018"},{"key":"10.1016\/j.jhep.2022.11.028_bib33","first-page":"1","article-title":"Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD","volume":"0","author":"Brunt","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib34","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/ajcp\/aqx011","article-title":"Interobserver variability in histologic evaluation of liver fibrosis using categorical and quantitative scores","volume":"147","author":"Pavlides","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jhep.2022.11.028_bib36","first-page":"1","article-title":"Principles for codevelopment of an in\u00a0vitro companion diagnostic device with a therapeutic product","year":"2016","journal-title":"FDA Draft Guid"},{"key":"10.1016\/j.jhep.2022.11.028_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpt.136","article-title":"Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization","volume":"98","author":"Amur","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.11.028_bib38","volume":"vols. 1\u201322","year":"2020"},{"key":"10.1016\/j.jhep.2022.11.028_bib39","volume":"vols. 1\u201315","year":"2020"},{"key":"10.1016\/j.jhep.2022.11.028_bib40","series-title":"Essential considerations for successful qualification of novel methodologies","year":"2017"},{"key":"10.1016\/j.jhep.2022.11.028_bib41","series-title":"Biomarker qualification: evidentiary framework - draft guidance","volume":"1\u201316","year":"2018"},{"key":"10.1016\/j.jhep.2022.11.028_bib42","year":"2022"},{"key":"10.1016\/j.jhep.2022.11.028_bib43","unstructured":"FDA. CDER Biomarker Qualification Program. https:\/\/www.fda.gov\/drugs\/drug-development-tool-ddt-qualification-programs\/biomarker-qualification-program."},{"key":"10.1016\/j.jhep.2022.11.028_bib44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/liv.12700","article-title":"Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C","volume":"35","author":"Nielsen","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.11.028_bib45","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jhep.2022.11.028_bib46","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib47","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jhep.2022.11.028_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.11.028_bib49","article-title":"Determining a healthy reference range and factors potentially influencing PRO-C3 - a biomarker of liver fibrosis","volume":"3","author":"Erhardtsen","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.11.028_bib50","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib51","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.11.028_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying\u00a0nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.11.028_bib53","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/liv.12760","article-title":"ELF score \u22659.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity","volume":"35","author":"Fagan","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.11.028_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD Registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2022.11.028_bib55","series-title":"Electronic source data in clinical investigations | FDA","year":"2013"},{"key":"10.1016\/j.jhep.2022.11.028_bib56","series-title":"Interference testing in clinical chemistry; approved guideline","year":"2005"},{"key":"10.1016\/j.jhep.2022.11.028_bib57","series-title":"Supplemental tables for interference testing in clinical chemistry","year":"2021"},{"key":"10.1016\/j.jhep.2022.11.028_bib58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-1872-0_15","article-title":"The European Medicines Agency experience with biomarker qualification","volume":"1243","author":"Manolis","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhep.2022.11.028_bib59","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/17425255.2018.1511701","article-title":"Biomarkers of drug-induced acute kidney injury: a regulatory perspective","volume":"14","author":"Blank","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822033256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822033256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:49:00Z","timestamp":1759175340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822033256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0168827822033256"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.11.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAFLD and NASH biomarker qualification in the LITMUS consortium \u2013 Lessons learned","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}